Stocks and Investing
Stocks and Investing
Thu, December 15, 2022
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Wed, December 14, 2022
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Alex Thompson Initiated (ACRS) at Strong Buy and Held Target at $29 on, Dec 14th, 2022
Alex Thompson of Stifel, Initiated "Aclaris Therapeutics, Inc." (ACRS) at Strong Buy and Held Target at $29 on, Dec 14th, 2022.
Alex has made no other calls on ACRS in the last 4 months.
There are 2 other peers that have a rating on ACRS. Out of the 2 peers that are also analyzing ACRS, 0 agree with Alex's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Alex
- Corinne Jenkins of "Goldman Sachs" Initiated at Strong Buy and Held Target at $25 on, Thursday, December 1st, 2022
- Julian Harrison of "BTIG" Initiated at Strong Buy and Held Target at $32 on, Thursday, October 6th, 2022
Contributing Sources